Skip to main content

Table 1 Clinical characteristics of patients with prostate cancer from whom samples of bone metastases were analyzed by Infinium Methylation EPIC arrays

From: A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

Clinical characteristics Hormone-naíve
n = 14
Short-term castrateda
n = 4
Castration-resistantb
n = 52
Age at diagnosis (years) 78 (74–80) 75 (72–76) 71 (64–75)
Age at metastasis surgery (years) 73 (68–80)
Serum PSA at diagnosis (ng/ml) 320 (82–980) 2300 (560–4300) 82 (40–510)
Serum PSA at metastasis surgery (ng/ml) 250 (82–630)
Bicalutamide prior to metastasis surgeryc
 Yes 0 0 28
 No 14 4 24
Radiation prior to metastasis surgeryd
 Yes 0 0 7
 No 14 4 45
Chemotherapy prior to metastasis surgery
 Yes 0 0 9
 No 14 4 43
Ra-223 prior to metastasis surgery
 Yes 0 0 6
 No 14 4 46
  1. Continuous values are given as median (25th; 75th percentiles)
  2. aShort-term treated patients had received androgen ablation therapy for 1–3 days before metastasis surgery
  3. bCastration-resistant patients had disease progression after long-term androgen deprivation therapy. First line androgen-deprivation therapy (ADT) includes surgical ablation, LHRH/GNRH agonist therapy, and therapy with anti-androgens
  4. cCastration therapy as stated above and bicalutamide for treatment of CRPC
  5. dRadiation towards operation site